Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Main Capital and Alfa eCare in connection with their strategic acquisition of Clinicbuddy
Mandate

Vinge has advised Main Capital and Alfa eCare in connection with their strategic acquisition of Clinicbuddy

June 22, 2021 Employment and Benefits M&A IT, Telecommunications and Outsourcing Commercial Agreements

The Alfa eCare group is a recognized eHealth software company, providing solutions to both public and private healthcare providers throughout Sweden.

Clinicbuddy provides various software solutions for care planning and digitization within healthcare, such as digital medical records and booking systems. The company’s products contribute to safe record keeping for care providers and more efficient and flexible systems for different types of clinics.

Vinge’s team consisted of Filip Öhrner, Kristina Ekberg and Eléonore Friberg (M&A), Ebba Svenburg (Employment), Karl-Hugo Engdahl (GDPR/IT), Rebecka Weitzberg (IP), Lisa Hörnqvist (Agreements) and Sara Dahlros Sköld (VDR).

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026